CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.069
NA - Nord America 13.040
EU - Europa 6.764
SA - Sud America 1.620
AF - Africa 211
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 10
Totale 36.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.684
CN - Cina 5.258
SG - Singapore 4.032
IT - Italia 2.140
HK - Hong Kong 1.772
GB - Regno Unito 1.368
BR - Brasile 1.274
KR - Corea 978
VN - Vietnam 948
FI - Finlandia 897
BD - Bangladesh 874
RU - Federazione Russa 389
DE - Germania 386
SE - Svezia 345
FR - Francia 337
IN - India 253
ID - Indonesia 242
NL - Olanda 212
CA - Canada 154
LT - Lituania 129
AR - Argentina 127
JP - Giappone 127
MX - Messico 116
TR - Turchia 112
UA - Ucraina 112
IQ - Iraq 101
IE - Irlanda 69
AT - Austria 64
AE - Emirati Arabi Uniti 53
ZA - Sudafrica 53
EC - Ecuador 52
PK - Pakistan 47
BG - Bulgaria 46
ES - Italia 43
AU - Australia 42
CO - Colombia 39
CZ - Repubblica Ceca 39
PL - Polonia 37
VE - Venezuela 32
CL - Cile 29
SA - Arabia Saudita 29
UZ - Uzbekistan 28
KE - Kenya 26
TN - Tunisia 26
EG - Egitto 25
MA - Marocco 25
PY - Paraguay 25
TW - Taiwan 24
MY - Malesia 21
NP - Nepal 18
PH - Filippine 18
TH - Thailandia 18
DZ - Algeria 17
PT - Portogallo 17
CH - Svizzera 16
UY - Uruguay 16
PE - Perù 15
JO - Giordania 14
RO - Romania 14
BE - Belgio 13
HN - Honduras 13
IL - Israele 13
OM - Oman 13
GT - Guatemala 12
JM - Giamaica 12
BY - Bielorussia 11
BO - Bolivia 10
CR - Costa Rica 10
DO - Repubblica Dominicana 10
GR - Grecia 10
HU - Ungheria 10
DK - Danimarca 9
AZ - Azerbaigian 8
KZ - Kazakistan 8
AL - Albania 7
HR - Croazia 7
NI - Nicaragua 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
TT - Trinidad e Tobago 7
AO - Angola 6
EU - Europa 6
KG - Kirghizistan 6
QA - Qatar 6
SK - Slovacchia (Repubblica Slovacca) 6
IR - Iran 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
LB - Libano 4
LV - Lettonia 4
MD - Moldavia 4
MN - Mongolia 4
NO - Norvegia 4
SV - El Salvador 4
UG - Uganda 4
BB - Barbados 3
BH - Bahrain 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
Totale 36.696
Salva come PNG Salva come JPEG
Città #
Hefei 3.388
Singapore 2.425
Santa Clara 1.873
Ashburn 1.703
Hong Kong 1.679
San Jose 1.161
Seoul 971
Helsinki 816
London 695
Council Bluffs 594
Fairfield 511
The Dalles 435
Southend 381
Los Angeles 359
Ho Chi Minh City 330
Beijing 318
Milan 280
Houston 276
Woodbridge 260
New York 253
Chicago 242
Seattle 227
Lauterbourg 221
Hanoi 207
Kent 197
Chandler 195
Nyköping 191
Buffalo 185
Jakarta 180
Wilmington 175
Dallas 171
Rome 161
Cambridge 159
Ann Arbor 158
Boardman 135
Jacksonville 131
São Paulo 129
Moscow 115
Dearborn 114
Munich 107
Salt Lake City 95
Shanghai 94
Amsterdam 90
Redondo Beach 81
Columbus 76
Modena 71
San Diego 70
Bologna 68
Dublin 68
Frankfurt am Main 68
Nuremberg 62
Tokyo 61
Mexico City 57
Reggio Emilia 57
Tampa 55
Elk Grove Village 54
Da Nang 51
Delhi 51
Atlanta 47
Washington 47
Phoenix 45
Guangzhou 44
Brooklyn 43
Hillsboro 42
Princeton 41
Sofia 40
Rio de Janeiro 39
Baghdad 38
Naples 38
Miami 37
Belo Horizonte 36
Miano 36
Florence 35
Izmir 35
Toronto 35
Turin 35
Boston 33
Orem 33
Kilburn 30
Lappeenranta 30
Eugene 29
Montreal 29
Mumbai 29
North Bergen 28
Charlotte 27
Palermo 27
Shenzhen 27
Vienna 26
Warsaw 26
Brasília 25
Curitiba 25
Haiphong 25
Johannesburg 25
Biên Hòa 24
Des Moines 24
Sterling 24
Tashkent 24
Turku 24
Bari 23
Guarulhos 23
Totale 24.690
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 432
Mucorales-specific T cells in patients with hematologic malignancies 367
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients 355
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 342
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 321
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 318
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 312
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 303
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 287
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 274
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 269
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 266
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 263
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 261
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group 260
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 257
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 254
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 252
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 240
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation 239
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 234
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 226
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 225
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 221
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 219
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 218
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 215
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 215
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 213
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 213
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 207
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 203
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 201
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 200
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 196
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 196
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 192
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 189
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG 188
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 187
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 186
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients 185
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 183
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 183
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 182
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 181
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 181
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 179
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 177
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 175
Advanced mast cell disease: An Italian Hematological Multicenter experience 167
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 167
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 166
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 164
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 163
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey 162
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 162
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial 158
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 157
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 157
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 157
Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression 152
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 151
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 151
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 149
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 148
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 148
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 148
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 148
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 145
FLAI induction regimen in elderly patients with acute myeloid leukemia 144
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial 144
Systemic antifungal treatment after posaconazole prophylaxis: Results from the SEIFEM 2010-C survey 144
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 143
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 142
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 142
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination 141
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 141
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 140
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia 139
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 138
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 138
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 138
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 137
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 137
Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study 136
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study 134
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 133
Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia 132
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 132
Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM) 132
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 132
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia 130
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 129
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax 129
Fungaemia in haematological malignancies: SEIFEM-2015 survey 128
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 126
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts 126
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 125
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 123
Totale 19.017
Salva come PNG Salva come JPEG
Categoria #
all - tutte 192.264
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 192.264
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022729 38 101 59 44 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/20259.165 218 117 96 624 1.549 1.063 390 347 1.016 886 1.539 1.320
2025/202620.269 1.801 1.492 2.461 2.005 1.240 1.267 2.716 854 1.550 1.661 1.641 1.581
2026/2027735 735 0 0 0 0 0 0 0 0 0 0 0
Totale 37.138